A xenograft model with aromatase overexpressing breast cancer cells has disclosed adaptive changes resulting in activation of alternate signaling pathways due to increased expression of e.g., EGFR, HER2 and IGF-IR (25). This evidence concerns the gene CYP19A1 and breast cancer.